These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10456880)

  • 1. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.
    Douce G; Giannelli V; Pizza M; Lewis D; Everest P; Rappuoli R; Dougan G
    Infect Immun; 1999 Sep; 67(9):4400-6. PubMed ID: 10456880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analysis of the role of ADP-ribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin.
    de Haan L; Feil IK; Verweij WR; Holtrop M; Hol WG; Agsteribbe E; Wilschut J
    Eur J Immunol; 1998 Apr; 28(4):1243-50. PubMed ID: 9565364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity.
    Ryan EJ; McNeela E; Pizza M; Rappuoli R; O'Neill L; Mills KH
    J Immunol; 2000 Nov; 165(10):5750-9. PubMed ID: 11067933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.
    Castagliuolo I; Sardina M; Brun P; DeRos C; Mastrotto C; Lovato L; Palù G
    Infect Immun; 2004 May; 72(5):2827-36. PubMed ID: 15102793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes.
    Park EJ; Chang JH; Kim JS; Yum JS; Chung SI
    Exp Mol Med; 2000 Jun; 32(2):72-8. PubMed ID: 10926118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.
    McCluskie MJ; Weeratna RD; Clements JD; Davis HL
    Vaccine; 2001 Jun; 19(27):3759-68. PubMed ID: 11395211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant effect of non-toxic mutants of E. coli heat-labile enterotoxin following intranasal, oral and intravaginal immunization.
    De Magistris MT; Pizza M; Douce G; Ghiara P; Dougan G; Rappuoli R
    Dev Biol Stand; 1998; 92():123-6. PubMed ID: 9554265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
    Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
    Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.
    Nawar HF; Arce S; Russell MW; Connell TD
    Infect Immun; 2007 Feb; 75(2):621-33. PubMed ID: 17118982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.
    Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW
    Infect Immun; 2000 Jan; 68(1):281-7. PubMed ID: 10603399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55.
    Neidleman JA; Vajdy M; Ugozzoli M; Ott G; O'Hagan D
    Immunology; 2000 Sep; 101(1):154-60. PubMed ID: 11012767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities.
    Nawar HF; Arce S; Russell MW; Connell TD
    Infect Immun; 2005 Mar; 73(3):1330-42. PubMed ID: 15731030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT).
    Cheng E; Cárdenas-Freytag L; Clements JD
    Vaccine; 1999 Aug; 18(1-2):38-49. PubMed ID: 10501233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses.
    Guerrero RA; Ball JM; Krater SS; Pacheco SE; Clements JD; Estes MK
    J Virol; 2001 Oct; 75(20):9713-22. PubMed ID: 11559804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge.
    Beignon AS; Briand JP; Muller S; Partidos CD
    Immunology; 2001 Mar; 102(3):344-51. PubMed ID: 11298834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen.
    Verweij WR; de Haan L; Holtrop M; Agsteribbe E; Brands R; van Scharrenburg GJ; Wilschut J
    Vaccine; 1998 Dec; 16(20):2069-76. PubMed ID: 9796066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of bacterial and tobacco plant cell line derived recombinant native and mutant Escherichia coli heat-labile toxin in chickens.
    Miller T; Fanton M; Nickelson S; Mason H; Webb S
    Avian Pathol; 2012 Oct; 41(5):441-9. PubMed ID: 22928883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.
    Norton EB; Lawson LB; Freytag LC; Clements JD
    Clin Vaccine Immunol; 2011 Apr; 18(4):546-51. PubMed ID: 21288994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response.
    Fromantin C; Jamot B; Cohen J; Piroth L; Pothier P; Kohli E
    J Virol; 2001 Nov; 75(22):11010-6. PubMed ID: 11602741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli.
    Douce G; Giuliani MM; Giannelli V; Pizza MG; Rappuoli R; Dougan G
    Vaccine; 1998 Jul; 16(11-12):1065-73. PubMed ID: 9682360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.